OCCIDENT’s portfolio company Tubulis raises more than €300 million
OCCIDENT participated in this incredible Series C round led by Venrock Healthcare Capital Partners to further develop antibody-drug conjugates (ADCs).
News
Thermosome reports encouraging data from Phase I trial
Early clinical data show encouraging efficacy and safety for THE001, supporting advancement into Phase 2 trials in advanced soft tissue sarcoma.
ReCatalyst establishes a strong Advisory Board
Four international industry experts will strengthen the company in the upcoming growth phase.
5th edition of the OCCIDENT Pitch Event in Munich
We had the opportunity to see 18 pitches from start-ups nominated by OCCIDENT, the Helmholtz Association and xista science ventures before spending the evening with inspiring networking.
Algiax presented promising results from Phase 2 study
The study with the lead compound AP-325 shows meaningful pain reduction in patients with peripheral post-surgical neuropathic pain, with fewer side effects.
Tubulis’ second drug candidate enters clinical evaluation
Tubulis advances its pipeline as TUB-030, a next-generation ADC targeting advanced solid tumors, enters Phase I/IIa trial.
OCCIDENT’s End-of-Year Message
As Science Investor, we build bridges of various kinds, overcoming challenges and bridging differences, thus connecting different worlds and perspectives.
OCCIDENT’s Annual Review and Christmas dinner
The OCCIDENT Team reviews the past eventful year and tunes in to Christmas. And at the same time, we are looking forward to the new opportunities that await us in the new year.
Tubulis enters into collaboration with Gilead Sciences
The agreement, valued at up to $415 million, combines Gilead's long-standing expertise with Tubulis' innovative technology to advance ADC treatment for solid tumors.